Edition:
United Kingdom

Aimmune Therapeutics Inc (AIMT.OQ)

AIMT.OQ on NASDAQ Stock Exchange Global Select Market

30.68USD
19 Jun 2018
Change (% chg)

$-0.09 (-0.29%)
Prev Close
$30.77
Open
$30.70
Day's High
$31.19
Day's Low
$30.29
Volume
185,345
Avg. Vol
281,504
52-wk High
$41.75
52-wk Low
$16.36

Chart for

About

Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company's therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is... (more)

Overall

Beta: --
Market Cap(Mil.): $1,281.57
Shares Outstanding(Mil.): 50.54
Dividend: --
Yield (%): --

Financials

  AIMT.OQ Industry Sector
P/E (TTM): -- 30.95 32.75
EPS (TTM): -2.24 -- --
ROI: -50.47 14.84 14.38
ROE: -50.82 16.34 16.07

BRIEF-Aimmune Therapeutics Reports Q1 Loss Per Share $0.92

* AIMMUNE THERAPEUTICS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS

08 May 2018

BRIEF-Aimmune Therapeutics Qtrly Loss Per Share $0.81

* AIMMUNE THERAPEUTICS ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

12 Mar 2018

BRIEF-Aimmune Therapeutics Announces Proposed Public Offering Of Common Stock

* AIMMUNE THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

20 Feb 2018

Aimmune's peanut allergy drug meets main goal, shares surge

U.S. drug developer Aimmune Therapeutics Inc said on Tuesday its peanut allergy drug met the main goal of an eagerly awaited late-stage study, sending its shares up 18 percent premarket.

20 Feb 2018

UPDATE 2-Aimmune's peanut allergy drug meets main goal, shares surge

Feb 20 U.S. drug developer Aimmune Therapeutics Inc said on Tuesday its peanut allergy drug met the main goal of an eagerly awaited late-stage study, sending its shares up 18 percent premarket.

20 Feb 2018

BRIEF-Aimmune Therapeutics' Phase 3 Palisade Trial Of Ar101 Meets Primary Endpoint In Patients With Peanut Allergy

* AIMMUNE THERAPEUTICS’ PIVOTAL PHASE 3 PALISADE TRIAL OF AR101 MEETS PRIMARY ENDPOINT IN PATIENTS WITH PEANUT ALLERGY

20 Feb 2018

Aimmune's peanut allergy drug meets main goal of key study

Feb 20 U.S. drug developer Aimmune Therapeutics Inc said on Tuesday its peanut allergy drug met the main goal of an eagerly awaited late-stage study.

20 Feb 2018

BRIEF-Aimmune Extends Supply Agreement With Golden Peanut And Tree Nuts For Experimental Allergy Treatment

* AIMMUNE THERAPEUTICS BROADENS AND EXTENDS SUPPLY AGREEMENT WITH GOLDEN PEANUT AND TREE NUTS FOR AR101 FOR PEANUT ALLERGY

10 Jan 2018

BRIEF-Aimmune Therapeutics Inc Files For Potential Mixed Shelf

* AIMMUNE THERAPEUTICS INC FILES FOR POTENTIAL MIXED SHELF, SIZE NOT DISCLOSED - SEC FILING Source text (http://bit.ly/2ClRCUj) Further company coverage:

28 Dec 2017

Competitors

  Price Chg
DBV Technologies SA (DBV.PA) €34.70 --

Earnings vs. Estimates